Department of Orthopedics, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, 130000, China.
Department of Breast and Thyroid Surgery, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, 130000, China.
Pharmacol Rep. 2023 Dec;75(6):1445-1453. doi: 10.1007/s43440-023-00534-9. Epub 2023 Nov 3.
Prostate cancer is the second most prevalent cancer in men worldwide. The TRIM (tripartite motif) family of proteins is involved in the regulation of various cellular processes, including antiviral immunity, apoptosis, and cancer progression. In recent years, several TRIM proteins have been found to play important roles in prostate cancer initiation and progression. TRIM proteins have indicated oncogenic activity in prostate cancer by enhancing androgen or estrogen receptor signaling and promoting cancer cell growth. Inhibition of TRIM proteins has been raised as a potential therapeutic strategy for the treatment of prostate cancer. Overall, these studies suggest that TRIM family proteins exert tumor-promoting effects in prostate cancer, and targeting these proteins can provide a promising therapeutic strategy for prostate cancer treatment. On the other hand, some TRIM proteins can be differentially expressed in prostate cancer cells compared to normal cells, thus providing novel diagnostic/prognostic biomarkers for prostate cancer.
前列腺癌是全球男性第二大常见癌症。三基序蛋白（TRIM）家族参与多种细胞过程的调节，包括抗病毒免疫、细胞凋亡和癌症进展。近年来，发现几种 TRIM 蛋白在前列腺癌的发生和发展中发挥重要作用。TRIM 蛋白通过增强雄激素或雌激素受体信号转导和促进癌细胞生长，表现出致癌活性。抑制 TRIM 蛋白已被提出作为治疗前列腺癌的潜在治疗策略。总的来说，这些研究表明 TRIM 家族蛋白在前列腺癌中发挥促肿瘤作用，针对这些蛋白可以为前列腺癌治疗提供有前途的治疗策略。另一方面，与正常细胞相比，一些 TRIM 蛋白在前列腺癌细胞中可以差异表达，因此为前列腺癌提供了新的诊断/预后生物标志物。
